Review



ve cadherin  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc ve cadherin
    Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology <t>and</t> <t>VE-cadherin</t> staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.
    Ve Cadherin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 562 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/VE-Cadherin+XP+Rabbit+mAb/pmc12810552-104-16-20
    Average 96 stars, based on 562 article reviews
    ve cadherin - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Ribbon-shaped microgels as bioinks for 3D bioprinting of anisotropic tissue structures"

    Article Title: Ribbon-shaped microgels as bioinks for 3D bioprinting of anisotropic tissue structures

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2025.12.040

    Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology and VE-cadherin staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.
    Figure Legend Snippet: Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology and VE-cadherin staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.

    Techniques Used: Staining

    Related Articles

    Blocking Assay:

    Article Title: STING–STAT3–SOX18 Axis Drives EndMT and Epigenetic Reprogramming in SAVI Lung Fibrosis
    Article Snippet: For each sample, 20 μg of total protein was analyzed by Western blot using a Bio-Rad 4–20% Mini-PROTEAN TGX Gel and subsequently transferred onto nitrocellulose membranes. .. After blocking with LI-COR blocking buffer, the membranes were incubated with primary antibodies for VE-cadherin (1:1000, CST, Cat2500S), CD31(1:1000, DAKO, Cat#M0823), SMA (1:2000, Abcam, Cat#ab7817), SM22 (1:1000, Abcam, Cat#ab14106), SOX18 (1:100, Santa Cruz, Cat#sc-166025), SLUG (1:1000, CST, Cat#9585S), P-STAT3 Y705 (1:1000, CST, Cat#9145S), STAT3 (1:1000, CST, Cat#9139S), P-STAT1 Y701 (1:1000, CST, Cat#9167S), STAT1(1:1000, CST, Cat#9172S), P-STING S366 (1:1000, CST, Cat#19781S), STING (1:1000, CST, Cat#13647S), P-TBK1 S172 (1:1000, CST, Cat#5483S), TBK1 (1:1000, CST, Cat#3504S), P-IRF3 S396 (1:1000, CST, Cat#4947S), and IRF3 (1:1000, CST, Cat#11904S) overnight at 4°C; these antibodies are listed in the Key Resource table. .. Western blot samples were lysed in CHAPS buffer containing protease and phosphatase inhibitor cocktails (Invitrogen).

    Article Title: Conformable Device for Independent Measurements of Mucosal and Vascular Barriers in a Complex In Vitro Intestinal Model.
    Article Snippet: .. Cells were then incubated overnight at 4◦C with primary antibody, Caco2/HT29-MTX cells were stained with tight junction protein ZO-1 (rabbit monoclonal anti-ZO1; abcam, ab221547; in 1% blocking solution); macrophages with IBA-1 (abcam) and HUVECs with VE-Cadherin (Rabbit monoclonal, VE-Cadherin (D87F2) XP, Cell Signaling Technology; in 2% BSA solution), all diluted in blocking solution. .. The next day, the samples were washed three times using DPBS and incubated with secondary antibody (goat anti-rabbit Alexa Fluor 488 (Invitrogen)) diluted 1:400 in blocking solution, for 1 h at room temperature protected from light.

    Incubation:

    Article Title: STING–STAT3–SOX18 Axis Drives EndMT and Epigenetic Reprogramming in SAVI Lung Fibrosis
    Article Snippet: For each sample, 20 μg of total protein was analyzed by Western blot using a Bio-Rad 4–20% Mini-PROTEAN TGX Gel and subsequently transferred onto nitrocellulose membranes. .. After blocking with LI-COR blocking buffer, the membranes were incubated with primary antibodies for VE-cadherin (1:1000, CST, Cat2500S), CD31(1:1000, DAKO, Cat#M0823), SMA (1:2000, Abcam, Cat#ab7817), SM22 (1:1000, Abcam, Cat#ab14106), SOX18 (1:100, Santa Cruz, Cat#sc-166025), SLUG (1:1000, CST, Cat#9585S), P-STAT3 Y705 (1:1000, CST, Cat#9145S), STAT3 (1:1000, CST, Cat#9139S), P-STAT1 Y701 (1:1000, CST, Cat#9167S), STAT1(1:1000, CST, Cat#9172S), P-STING S366 (1:1000, CST, Cat#19781S), STING (1:1000, CST, Cat#13647S), P-TBK1 S172 (1:1000, CST, Cat#5483S), TBK1 (1:1000, CST, Cat#3504S), P-IRF3 S396 (1:1000, CST, Cat#4947S), and IRF3 (1:1000, CST, Cat#11904S) overnight at 4°C; these antibodies are listed in the Key Resource table. .. Western blot samples were lysed in CHAPS buffer containing protease and phosphatase inhibitor cocktails (Invitrogen).

    Article Title: Lactate Promotes Endothelial-Mesenchymal Transition via Mediating Twist1 Lactylation in Hypoxic Pulmonary Hypertension.
    Article Snippet: .. The membranes were then incubated overnight at 4 ◦C with the following specific primary antibodies: Endothelial cell markers: CD31 (1:1000, 11265-1-AP, Proteintech), VE-Cadherin (1:1000, 2500, Cell Signaling Technology, Danvers, MA, USA); Mesenchymal cell markers: α-SMA (1:2000, ab21027, Abcam), FSP1 (1:1000, ab27957, Abcam); SM22-α (1:1000, 10493-1-AP, Proteintech); Vimentin (1:1000, 5741, Cell Signaling Technology, Danvers, MA, USA); TGF-β signaling pathway-related proteins: TGF-β1 (1:1000, 10188-1-AP, proteintech), p-Smad2 (1:1000, 18338, Cell Signaling Technology), Smad2 (1:1000,12570-1-AP, proteintech), Total-Smad2/3 (1:1000, 3102, Cell Signaling Technology); Twist1 (1:1000, 25465-1-AP, Proteintech), β-actin (1:500; SC-130657, Santacruz), H3 (1:1000, 17168-1-AP, Proteintech). .. Total protein was extracted from cells or tissues using RIPA lysis buffer (P0013B, Beyotime Biotechnology) containing protease and phosphatase inhibitors (P1046, Beyotime Biotechnology) on ice.

    Article Title: SARS−CoV−2 spike S1-mediated HIF−2α activation in retinal endothelial cells suggests a mechanism contributing to post−COVID endothelial dysfunction
    Article Snippet: .. Subsequently, cells were incubated with primary antibodies against NF-κB, HIF-1α, HIF-2α, BNIP-3, GLUT-1, VEGFR2, claudin-5, and VE-cadherin (all from Cell Signaling; Cat. No. 8242, 36169, 71565, 44060, 73015, 2479, 49564, 2500, respectively), or PDK-1 (Abcam, Cat. No. ab202468) in an antibody dilution buffer containing 1% BSA and 0.1% Triton X-100 in PBS, overnight, at 4 °C. .. Next, cells were washed three times in PBS and incubated with a fluorescently tagged goat anti-rabbit secondary antibody (Cell Signaling, Cat. No. 4412S) in antibody dilution buffer containing 1% BSA in PBS for 1 hour at room temperature protected from light.

    Article Title: Dermal Microvascular Responses of Human IPSC-Derived Skin Organoids to Inflammation and Injury.
    Article Snippet: Cutaneous dermal microvascular responses are critical to common inflammatory skin conditions and effective wound healing.. However, few laboratory models effectively recreate the spatially intact microenvironment essential for genesis and function of the human dermal microcirculation.. Recently, stem cell-derived skin organoids (SKOs) have been developed that possess many microanatomical and cellular features of native human skin, including hair-forming epidermis and an underlying dermal layer containing endothelial-lined channels.

    Article Title: Conformable Device for Independent Measurements of Mucosal and Vascular Barriers in a Complex In Vitro Intestinal Model.
    Article Snippet: .. Cells were then incubated overnight at 4◦C with primary antibody, Caco2/HT29-MTX cells were stained with tight junction protein ZO-1 (rabbit monoclonal anti-ZO1; abcam, ab221547; in 1% blocking solution); macrophages with IBA-1 (abcam) and HUVECs with VE-Cadherin (Rabbit monoclonal, VE-Cadherin (D87F2) XP, Cell Signaling Technology; in 2% BSA solution), all diluted in blocking solution. .. The next day, the samples were washed three times using DPBS and incubated with secondary antibody (goat anti-rabbit Alexa Fluor 488 (Invitrogen)) diluted 1:400 in blocking solution, for 1 h at room temperature protected from light.

    Article Title: Lactate Promotes Endothelial-Mesenchymal Transition via Mediating Twist1 Lactylation in Hypoxic Pulmonary Hypertension
    Article Snippet: .. The membranes were then incubated overnight at 4 °C with the following specific primary antibodies: Endothelial cell markers: CD31 (1:1000, 11265-1-AP, Proteintech), VE-Cadherin (1:1000, 2500, Cell Signaling Technology, Danvers, MA, USA); Mesenchymal cell markers: α-SMA (1:2000, ab21027, Abcam), FSP1 (1:1000, ab27957, Abcam); SM22-α (1:1000, 10493-1-AP, Proteintech); Vimentin (1:1000, 5741, Cell Signaling Technology, Danvers, MA, USA); TGF-β signaling pathway-related proteins: TGF-β1 (1:1000, 10188-1-AP, proteintech), p-Smad2 (1:1000, 18338, Cell Signaling Technology), Smad2 (1:1000,12570-1-AP, proteintech), Total-Smad2/3 (1:1000, 3102, Cell Signaling Technology); Twist1 (1:1000, 25465-1-AP, Proteintech), β-actin (1:500; SC-130657, Santacruz), H3 (1:1000, 17168-1-AP, Proteintech). .. Pan-kla (1:1000, PTM-1401, PTM BIO), CBP (1:1000, 7389, Cell Signaling Technology), p300 (1:1000, 20695-1-AP, Proteintech).

    Staining:

    Article Title: Conformable Device for Independent Measurements of Mucosal and Vascular Barriers in a Complex In Vitro Intestinal Model.
    Article Snippet: .. Cells were then incubated overnight at 4◦C with primary antibody, Caco2/HT29-MTX cells were stained with tight junction protein ZO-1 (rabbit monoclonal anti-ZO1; abcam, ab221547; in 1% blocking solution); macrophages with IBA-1 (abcam) and HUVECs with VE-Cadherin (Rabbit monoclonal, VE-Cadherin (D87F2) XP, Cell Signaling Technology; in 2% BSA solution), all diluted in blocking solution. .. The next day, the samples were washed three times using DPBS and incubated with secondary antibody (goat anti-rabbit Alexa Fluor 488 (Invitrogen)) diluted 1:400 in blocking solution, for 1 h at room temperature protected from light.

    Immunostaining:

    Article Title: Ribbon-shaped microgels as bioinks for 3D bioprinting of anisotropic tissue structures
    Article Snippet: .. For analyzing cell alignment of HUVEC and MSC, immunostaining of actin (ActinRedTM 555 ReadyProbes, ThermoFisher) and VE-cadherin (1:400, 2500 T, Cell Signaling) were performed on the scaffolds. .. Goat anti-rabbit IgG AlexaFluor 647 (1:500, A-21245, Invitrogen) was used as secondary antibody.



    Similar Products

    cd144 (ve-cadherin) antibody, anti-human, reafinity  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd144 (ve-cadherin) antibody, anti-human, reafinity
    Cd144 (Ve Cadherin) Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/CD144+(VE-Cadherin)+Antibody%2C+anti-human%2C+REAfinity/custom%40130-135-356%4041168363
    Average 94 stars, based on 1 article reviews
    cd144 (ve-cadherin) antibody, anti-human, reafinity - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human ve-cadherin antibody  (Bio-Techne corporation)
    99
    Bio-Techne corporation human ve-cadherin antibody
    Human Ve Cadherin Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/Human+VE-Cadherin+Antibody/custom%40mab9381%4042103601
    Average 99 stars, based on 1 article reviews
    human ve-cadherin antibody - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    ve cadherin cre  (Jackson Laboratory)
    86
    Jackson Laboratory ve cadherin cre
    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed <t>to</t> <t>either</t> <t>VE-Cadherin‐Cre</t> (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.
    Ve Cadherin Cre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/cadherin+cre+ve/pmc13268903-39-1-5
    Average 86 stars, based on 1 article reviews
    ve cadherin cre - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ve cadherin cdh5 cre mice  (Jackson Laboratory)
    86
    Jackson Laboratory ve cadherin cdh5 cre mice
    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed <t>to</t> <t>either</t> <t>VE-Cadherin‐Cre</t> (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.
    Ve Cadherin Cdh5 Cre Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/cadherin+cre+ve/pm42161931-790-13-16
    Average 86 stars, based on 1 article reviews
    ve cadherin cdh5 cre mice - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ve cadherin  (Adheren Inc)
    86
    Adheren Inc ve cadherin
    HFPF disrupts <t>VE-cadherin-mediated</t> adherens junctions (A) Immunostaining of VE-cadherin (green) and phalloidin (red) after 24 h HFPF treatment. Scale bars, 100 μm. (B) Western blot analysis of VE-cadherin expression. (C) Fractionation analysis shows membranous and cytosolic VE-cadherin levels. Na + /K + -ATPase and GAPDH served as loading controls. Data means SEM. ∗ p < 0.05 and ∗∗ p < 0.01.
    Ve Cadherin, supplied by Adheren Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/cadherin+ve/pmc13122223-104-8-0
    Average 86 stars, based on 1 article reviews
    ve cadherin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    cells  (Miltenyi Biotec)
    94
    Miltenyi Biotec cells
    HFPF disrupts <t>VE-cadherin-mediated</t> adherens junctions (A) Immunostaining of VE-cadherin (green) and phalloidin (red) after 24 h HFPF treatment. Scale bars, 100 μm. (B) Western blot analysis of VE-cadherin expression. (C) Fractionation analysis shows membranous and cytosolic VE-cadherin levels. Na + /K + -ATPase and GAPDH served as loading controls. Data means SEM. ∗ p < 0.05 and ∗∗ p < 0.01.
    Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/CD144+(VE-Cadherin)+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__05__14__725187-84-2-8
    Average 94 stars, based on 1 article reviews
    cells - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti human cd144 microbeads  (Miltenyi Biotec)
    95
    Miltenyi Biotec anti human cd144 microbeads
    (A) Schematic of directed differentiation protocol to generate hiEndos. (B) Phase contrast images during the indicated day of differentiation. White dashed square represents region magnified in insets. Scale bar: 50um. (C-E) RT-qPCR for the indicated primers using RNA isolated from cells on each day of differentiation, purified hiEndos at P0 and P5, and HUVECs. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. (F) Flow cytometry of hiEndos using antibodies against the human endothelial lineage markers CD31 and <t>CD144</t> (right) and isotype controls (left), N=4 biological replicates from distinct differentiations. (G) Immunostaining of hiEndos for human CD31 (green, left) and CD144 (red, right). Hoechst stains nuclei (blue). Scale bar 10um. N=3 biological replicates. (H) Capillary tube formation assay on 3D Matrigel. Scale bar 50um. N=4 biological replicates. (I-J) Human CD31 and acetylated LDL uptake in hiEndos measured by flow cytomtetry (I) or fluorescence microscopy (J). Scale bar 50um. N=8 biological replicates. (K) Schematic of experiment to test the impact of Notch (DAPT) and TGF-beta (SB431542) inhibition on hiEndo expansion (top). Quantification of CD31 and CD144 double-positive cells by flow cytometry (left) and cumulative hiEndo yield (right) at each passage grown in the indicated media conditions. N=2 experimental replicates from independent wells of the same differentiation, representative data shown from 3 independent differentiations. (L) Quantification of total hiEndo yield per input hiEndo in each media. ** p<0.01 using one-way Anova and Tukey’s multiple comparison test. (M) RT-qPCR of arterial and venous markers after serial passaging in SD medium. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. ** p<0.01, *** p<0.001, **** p<0.0001, one-way Anova and Tukey’s multiple comparison test. Abbreviations: hiPSC (human induced pluripotent stem cell), CHIR (CHIR99021), P (passage), HUVEC (human umbilical vein endothelial cells), AcLDL (acetylated low-density lipoprotein), SB (SB431542).
    Anti Human Cd144 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/CD144+(VE-Cadherin)+MicroBeads%2C+human/bio_rxiv__64898__2026__04__29__721664-241-13-17
    Average 95 stars, based on 1 article reviews
    anti human cd144 microbeads - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    ve cadherin  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc ve cadherin
    Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology <t>and</t> <t>VE-cadherin</t> staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.
    Ve Cadherin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/VE-Cadherin+XP+Rabbit+mAb/pmc12810552-104-16-20
    Average 96 stars, based on 1 article reviews
    ve cadherin - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    af1002  (R&D Systems)
    95
    R&D Systems af1002
    Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology <t>and</t> <t>VE-cadherin</t> staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.
    Af1002, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ve+cadherin/Mouse+VE-Cadherin+Antibody/pmc13049445-112-18-16
    Average 95 stars, based on 1 article reviews
    af1002 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.

    Journal: Frontiers in Immunology

    Article Title: Endothelial cell, but not neutrophil, programmed cell death receptor-ligand 1 loss has a morbid impact on experimental murine shock/sepsis-induced lung injury

    doi: 10.3389/fimmu.2026.1816915

    Figure Lengend Snippet: Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.

    Article Snippet: The VE-Cadherin‐Cre (Strain #:006137; RRID: IMSR_JAX:006137) and the S100a8-Cre (Strain #:021614; RRID: IMSR_JAX:021614) breeder mouse strains were also obtained from The Jackson Laboratory (see ).

    Techniques: Knock-Out, Expressing, Binding Assay

    HFPF disrupts VE-cadherin-mediated adherens junctions (A) Immunostaining of VE-cadherin (green) and phalloidin (red) after 24 h HFPF treatment. Scale bars, 100 μm. (B) Western blot analysis of VE-cadherin expression. (C) Fractionation analysis shows membranous and cytosolic VE-cadherin levels. Na + /K + -ATPase and GAPDH served as loading controls. Data means SEM. ∗ p < 0.05 and ∗∗ p < 0.01.

    Journal: iScience

    Article Title: Heart failure pleural fluid impairs endothelial barrier through miR 501-3p mediated ZO 1 remodeling

    doi: 10.1016/j.isci.2026.115549

    Figure Lengend Snippet: HFPF disrupts VE-cadherin-mediated adherens junctions (A) Immunostaining of VE-cadherin (green) and phalloidin (red) after 24 h HFPF treatment. Scale bars, 100 μm. (B) Western blot analysis of VE-cadherin expression. (C) Fractionation analysis shows membranous and cytosolic VE-cadherin levels. Na + /K + -ATPase and GAPDH served as loading controls. Data means SEM. ∗ p < 0.05 and ∗∗ p < 0.01.

    Article Snippet: Adheren junctions modulate cell adhesion via cadherins, and VE-cadherin is one of the major cadherins in endothelial cells.

    Techniques: Immunostaining, Western Blot, Expressing, Fractionation

    (A) Schematic of directed differentiation protocol to generate hiEndos. (B) Phase contrast images during the indicated day of differentiation. White dashed square represents region magnified in insets. Scale bar: 50um. (C-E) RT-qPCR for the indicated primers using RNA isolated from cells on each day of differentiation, purified hiEndos at P0 and P5, and HUVECs. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. (F) Flow cytometry of hiEndos using antibodies against the human endothelial lineage markers CD31 and CD144 (right) and isotype controls (left), N=4 biological replicates from distinct differentiations. (G) Immunostaining of hiEndos for human CD31 (green, left) and CD144 (red, right). Hoechst stains nuclei (blue). Scale bar 10um. N=3 biological replicates. (H) Capillary tube formation assay on 3D Matrigel. Scale bar 50um. N=4 biological replicates. (I-J) Human CD31 and acetylated LDL uptake in hiEndos measured by flow cytomtetry (I) or fluorescence microscopy (J). Scale bar 50um. N=8 biological replicates. (K) Schematic of experiment to test the impact of Notch (DAPT) and TGF-beta (SB431542) inhibition on hiEndo expansion (top). Quantification of CD31 and CD144 double-positive cells by flow cytometry (left) and cumulative hiEndo yield (right) at each passage grown in the indicated media conditions. N=2 experimental replicates from independent wells of the same differentiation, representative data shown from 3 independent differentiations. (L) Quantification of total hiEndo yield per input hiEndo in each media. ** p<0.01 using one-way Anova and Tukey’s multiple comparison test. (M) RT-qPCR of arterial and venous markers after serial passaging in SD medium. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. ** p<0.01, *** p<0.001, **** p<0.0001, one-way Anova and Tukey’s multiple comparison test. Abbreviations: hiPSC (human induced pluripotent stem cell), CHIR (CHIR99021), P (passage), HUVEC (human umbilical vein endothelial cells), AcLDL (acetylated low-density lipoprotein), SB (SB431542).

    Journal: bioRxiv

    Article Title: A chimeric human-mouse lung vascular model using induced pluripotent stem cells reveals insights into the pathogenesis of BMPR2 -related pulmonary hypertension

    doi: 10.64898/2026.04.29.721664

    Figure Lengend Snippet: (A) Schematic of directed differentiation protocol to generate hiEndos. (B) Phase contrast images during the indicated day of differentiation. White dashed square represents region magnified in insets. Scale bar: 50um. (C-E) RT-qPCR for the indicated primers using RNA isolated from cells on each day of differentiation, purified hiEndos at P0 and P5, and HUVECs. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. (F) Flow cytometry of hiEndos using antibodies against the human endothelial lineage markers CD31 and CD144 (right) and isotype controls (left), N=4 biological replicates from distinct differentiations. (G) Immunostaining of hiEndos for human CD31 (green, left) and CD144 (red, right). Hoechst stains nuclei (blue). Scale bar 10um. N=3 biological replicates. (H) Capillary tube formation assay on 3D Matrigel. Scale bar 50um. N=4 biological replicates. (I-J) Human CD31 and acetylated LDL uptake in hiEndos measured by flow cytomtetry (I) or fluorescence microscopy (J). Scale bar 50um. N=8 biological replicates. (K) Schematic of experiment to test the impact of Notch (DAPT) and TGF-beta (SB431542) inhibition on hiEndo expansion (top). Quantification of CD31 and CD144 double-positive cells by flow cytometry (left) and cumulative hiEndo yield (right) at each passage grown in the indicated media conditions. N=2 experimental replicates from independent wells of the same differentiation, representative data shown from 3 independent differentiations. (L) Quantification of total hiEndo yield per input hiEndo in each media. ** p<0.01 using one-way Anova and Tukey’s multiple comparison test. (M) RT-qPCR of arterial and venous markers after serial passaging in SD medium. N=4 experimental replicates from independent wells of the same differentiation, representative results from two independent differentiations. ** p<0.01, *** p<0.001, **** p<0.0001, one-way Anova and Tukey’s multiple comparison test. Abbreviations: hiPSC (human induced pluripotent stem cell), CHIR (CHIR99021), P (passage), HUVEC (human umbilical vein endothelial cells), AcLDL (acetylated low-density lipoprotein), SB (SB431542).

    Article Snippet: The cell pellet was then incubated with anti-human CD31 (1:10, Miltenyi, #130-091-935) and anti-human CD144 microbeads (1:10, Miltenyi, #130-097-857) diluted in EGM2 medium (50uL total volume per well of a 6-well plate, Lonza, #CC-3162) for 20 minutes.

    Techniques: Quantitative RT-PCR, Isolation, Purification, Flow Cytometry, Immunostaining, Capillary Tube Formation Assay, Fluorescence, Microscopy, Inhibition, Comparison, Passaging

    (A-C) Fold change in the expression of indicated transcripts in hiPSC-derived cells (BU3 clone) on each day of hiEndo differentiation, in purified hiEndos at P0 and P5, and in HUVECs (RT-qPCR). N=4 experimental replicates from independent wells of the same differentiation. (D) Quantitation of hiEndo differentiation efficiency on day 5 of differentiation across 12 distinct differentiations. (E) Flow cytometry of human CD31, human CD144, and isotype controls pre- and post-MACs purification of hiEndos on day 5 of the differentiation. N=1. (F) Phase contrast microscopy of BU3 hiEndos showing cobblestone morphology. Scale bar 50um. (G) Flow cytometry of human CD31, human CD44, and isotype controls in BU3 hiEndos, the plot is representative of 4 experimental replicates of independent wells from the same differentiation. (H) Quantification of the percent of CD31/CD144 double positive hiEndos by flow cytometry at each passage. N=1 differentiation (BU1). (I) Phase contrast microscopy of BU1 hiEndos at sequential passages. Scale bar 50um. Results are representative of 2 experimental replicates of independent wells from the same differentiation. (J) RT-qPCR analysis of fold change in transcript expression of markers of fibroblast and smooth muscle identity in hiEndos at sequential passages. N=2 experimental replicates of independent wells from the same differentiation. **** p<0.0001 by one-way Anova with Tukey’s multiple comparisons.

    Journal: bioRxiv

    Article Title: A chimeric human-mouse lung vascular model using induced pluripotent stem cells reveals insights into the pathogenesis of BMPR2 -related pulmonary hypertension

    doi: 10.64898/2026.04.29.721664

    Figure Lengend Snippet: (A-C) Fold change in the expression of indicated transcripts in hiPSC-derived cells (BU3 clone) on each day of hiEndo differentiation, in purified hiEndos at P0 and P5, and in HUVECs (RT-qPCR). N=4 experimental replicates from independent wells of the same differentiation. (D) Quantitation of hiEndo differentiation efficiency on day 5 of differentiation across 12 distinct differentiations. (E) Flow cytometry of human CD31, human CD144, and isotype controls pre- and post-MACs purification of hiEndos on day 5 of the differentiation. N=1. (F) Phase contrast microscopy of BU3 hiEndos showing cobblestone morphology. Scale bar 50um. (G) Flow cytometry of human CD31, human CD44, and isotype controls in BU3 hiEndos, the plot is representative of 4 experimental replicates of independent wells from the same differentiation. (H) Quantification of the percent of CD31/CD144 double positive hiEndos by flow cytometry at each passage. N=1 differentiation (BU1). (I) Phase contrast microscopy of BU1 hiEndos at sequential passages. Scale bar 50um. Results are representative of 2 experimental replicates of independent wells from the same differentiation. (J) RT-qPCR analysis of fold change in transcript expression of markers of fibroblast and smooth muscle identity in hiEndos at sequential passages. N=2 experimental replicates of independent wells from the same differentiation. **** p<0.0001 by one-way Anova with Tukey’s multiple comparisons.

    Article Snippet: The cell pellet was then incubated with anti-human CD31 (1:10, Miltenyi, #130-091-935) and anti-human CD144 microbeads (1:10, Miltenyi, #130-097-857) diluted in EGM2 medium (50uL total volume per well of a 6-well plate, Lonza, #CC-3162) for 20 minutes.

    Techniques: Expressing, Derivative Assay, Purification, Quantitative RT-PCR, Quantitation Assay, Flow Cytometry, Microscopy

    Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology and VE-cadherin staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.

    Journal: Bioactive Materials

    Article Title: Ribbon-shaped microgels as bioinks for 3D bioprinting of anisotropic tissue structures

    doi: 10.1016/j.bioactmat.2025.12.040

    Figure Lengend Snippet: Effect of extrusion process on μRB bioink and cell alignment. (A) Schematic of MSCs encapsulated in μRB bioink with HUVECs seeded on top of the printed scaffolds. (B) Live cell staining of MSC alignment on individual μRBs (Scale bar = 100 μm). (C) Distribution of MSC cell length (n = 250 per group); p-values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗∗∗p < 0.0001. (D) Cell orientation relative to μRB orientation, where 0° is parallel to the axis of the μRB (n = 250 per group). (E) Confocal images of F-Actin staining for cell morphology and VE-cadherin staining for endothelial cell junctions. Color survey visualization of directional analysis conducted using OrientationJ (Scale bar = 200 μm). (F, G) Quantification of F-actin and VE-Cadherin alignment. For alignment quantification (n = 10 per group) data reported as mean ± S.D., statistical analysis by Watson–Wheeler test, ∗p ≤ 0.05.

    Article Snippet: For analyzing cell alignment of HUVEC and MSC, immunostaining of actin (ActinRedTM 555 ReadyProbes, ThermoFisher) and VE-cadherin (1:400, 2500 T, Cell Signaling) were performed on the scaffolds.

    Techniques: Staining